PHC Corporation’s Biomedical Division, PHCbi, has made a significant advancement in the field of cell culture with the introduction of LiCellGrow, a cell expansion system tailored specifically for research applications. Initially available in Japan, this innovative system aims to enhance the development of cell and gene therapies across various global markets.
Enhancing Cell and Gene Therapy Production
LiCellGrow is engineered to facilitate the quality production of cell and gene therapies. By providing developers with the ability to automatically monitor and control culture conditions, it allows for real-time visualization of metabolic changes in cells. This level of precision is crucial for optimizing the development process and ensuring that therapies meet the required standards for efficacy and safety.
Advanced Monitoring Technology
At the heart of LiCellGrow is its In-Line monitoring technology, which continuously tracks glucose and lactate concentrations—key indicators of cellular metabolism. By leveraging over thirty years of expertise in blood glucose sensor innovation, PHCbi has created a system that not only gathers data but also utilizes it for real-time adjustments to the cell culture medium. This proactive approach enhances the consistency of product quality and adheres to quality by design principles essential for robust manufacturing processes.
Real-Time Data Integration
The system’s capability to monitor metabolic data in real time allows for timely adjustments in medium exchange. This dynamic adaptation promotes a stable environment for cell growth, ultimately leading to better outcomes in product quality. The integration of real-time analytics simplifies the complexity often associated with traditional cell culture methods, making it easier for researchers to achieve their objectives.
User-Friendly Design
LiCellGrow’s single-use design features dedicated culture bags that can be easily incorporated into standard CO₂ incubators, eliminating the need for specialized facilities. This convenience not only streamlines the research process but also minimizes contamination risks associated with reusable systems. By making the technology accessible, PHCbi is fostering a more efficient research environment.
Future Developments on the Horizon
Looking ahead, PHCbi plans to broaden its product range between late 2026 and early 2028, introducing additional features such as culture bags with filtration functions, dissolved oxygen meter units, and cGMP-compliant consumables. This expansion reflects the company’s commitment to staying at the forefront of bioprocessing technology, continually addressing the evolving needs of therapy developers.
Industry Impact and Commitment
Chikara Takauo, director of PHC Corporation and head of PHCbi, expressed enthusiasm for the launch of LiCellGrow. He emphasized the system’s potential to address common challenges faced by therapy developers, particularly in areas of quality, cost, and delivery of cell and gene therapies. The introduction of LiCellGrow marks a critical milestone in enhancing the efficiency, reliability, and scalability of cell and gene therapy manufacturing.
Conclusion
The launch of LiCellGrow represents a transformative step for researchers in the biotech industry. By enabling precise control over cell culture conditions and providing real-time metabolic data, PHCbi is paving the way for more effective cell and gene therapy development. As the company continues to innovate, the future holds great promise for advanced therapies that can tackle even the most challenging medical conditions.
- LiCellGrow enhances quality production of cell and gene therapies.
- Real-time monitoring optimizes cell culture conditions.
- Single-use design simplifies usage and reduces contamination risks.
- PHCbi plans to expand its offerings with advanced features by 2028.
- Commitment to improving efficiency and scalability in therapy manufacturing is a key focus.
Read more → www.yahoo.com